Alzheimer’s disease is the most common form of dementia and affects millions of people around the world. It slowly damages the brain and leads to problems with memory, thinking, and everyday activities.
Scientists have studied Alzheimer’s disease for decades, yet many questions remain about why the illness progresses faster in some people than in others. One long‑standing mystery is why women are more likely to develop Alzheimer’s disease than men.
A new study from researchers at Mayo Clinic offers an important clue. The study suggests that a protein linked to Parkinson’s disease may play a major role in speeding up Alzheimer’s‑related brain damage in women. The research was published in the medical journal JAMA Network Open.
Doctors have known for many years that Alzheimer’s disease is connected to abnormal protein buildup in the brain. One of the most important proteins involved is called tau. In healthy brains, tau helps support the structure of nerve cells.
But in Alzheimer’s disease, tau proteins can change shape and form tangled clumps inside brain cells. These tangles disrupt communication between cells and eventually lead to the death of brain tissue.
Another protein, called alpha‑synuclein, is usually linked to Parkinson’s disease and a related condition known as dementia with Lewy bodies. Like tau, alpha‑synuclein normally has useful functions in the brain. However, when it becomes abnormal, it can fold incorrectly and form sticky clumps that damage nerve cells.
In recent years, scientists have realized that many people with Alzheimer’s disease also develop abnormal alpha‑synuclein buildup. This means that some patients may actually have more than one type of brain disease happening at the same time. Researchers call this situation “co‑pathology,” meaning multiple disease processes occur together in the brain.
The Mayo Clinic research team wanted to understand whether the presence of both abnormal proteins—tau and alpha‑synuclein—might affect how quickly Alzheimer’s disease progresses. They also wanted to know whether the effects might be different for men and women.
To answer these questions, the scientists analyzed data from 415 volunteers who were part of the Alzheimer’s Disease Neuroimaging Initiative. This is a large national research program that follows people over many years and collects detailed information about brain changes, memory performance, and biological markers of disease.
Participants in the study underwent special brain scans that allowed researchers to measure how much tau protein was building up in different parts of the brain. They also had spinal fluid tests, which can detect abnormal levels of alpha‑synuclein and other proteins related to neurodegenerative diseases.
The results were striking. About 17 percent of the participants showed signs of abnormal alpha‑synuclein in addition to Alzheimer’s‑related changes. When researchers looked at how quickly tau protein accumulated in the brain, they noticed a dramatic difference between women and men.
Women who had both Alzheimer’s‑related changes and abnormal alpha‑synuclein showed extremely rapid progression of tau buildup. In some cases, the rate of progression was up to twenty times faster than what researchers observed in other participants. In contrast, men with the same combination of protein abnormalities did not show the same rapid increase.
This finding suggests that the interaction between these two proteins may create a particularly harmful environment in the brains of women. When both abnormal tau and alpha‑synuclein are present, the disease process may accelerate dramatically.
Dr. Kejal Kantarci, a neuroradiologist at Mayo Clinic and senior author of the study, explained that understanding these differences is important for developing better treatments.
Advanced brain imaging techniques allow researchers to track how Alzheimer’s disease spreads through the brain over time. By studying these patterns, scientists can learn how different biological factors influence disease progression.
The researchers believe these sex‑specific differences could help explain why women represent nearly two‑thirds of people living with Alzheimer’s disease in the United States.
For many years, this difference was often explained mainly by the fact that women tend to live longer than men. However, the new findings suggest that biological differences may also play an important role.
The study’s first author, Dr. Elijah Mak, noted that understanding why women may be more vulnerable could open new directions for research. If scientists can identify exactly how these proteins interact to accelerate brain damage, they may discover new targets for future treatments.
The research team is now exploring whether the same sex‑related patterns appear in people with dementia with Lewy bodies. In that disease, alpha‑synuclein is the main driver of brain damage rather than a secondary factor. Studying these patients may help determine whether the protein interaction seen in Alzheimer’s disease is part of a broader biological pattern.
Overall, the study highlights how complex neurodegenerative diseases can be. Alzheimer’s disease is not caused by a single factor but by a combination of biological processes that may interact in different ways in different people.
The findings are important because they suggest that Alzheimer’s disease may not progress in exactly the same way in everyone. Women and men may experience different biological pathways that influence how quickly the disease spreads in the brain.
However, the study also has some limitations. The research was based on observational data from existing participants rather than a controlled clinical trial.
This means that while the findings show strong associations, they cannot yet prove exactly how the protein interaction causes faster disease progression. Larger studies and further experiments will be needed to confirm the results and understand the underlying mechanisms.
Even so, the research provides an important new piece of the Alzheimer’s puzzle. By identifying factors that influence how quickly brain damage occurs, scientists may eventually be able to design more personalized treatments that consider each patient’s biology, including sex‑related differences.
In the future, clinical trials may also need to consider these differences when testing new therapies. Treatments that work well for one group of patients may not work the same way for another group if the disease process itself behaves differently.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
The findings of this study were published in JAMA Network Open.
Copyright © 2026 Knowridge Science Report. All rights reserved.
